Literature DB >> 10234625

Enzyme replacement therapy in type III Gaucher disease.

A Tylki-Szymańska1, B Czartoryska.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10234625     DOI： 10.1023/a:1005495229655

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  3 in total

1.  Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.

Authors:  P Kaplan; A Mazur; O Manor; J Charrow; J Esplin; T J Gribble; R S Wappner; J S Wisch; N J Weinreb
Journal:  J Pediatr       Date:  1996-07       Impact factor: 4.406

2.  Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease.

Authors:  A Erikson; M Aström; J E Månsson
Journal:  Neuropediatrics       Date:  1995-08       Impact factor: 1.947

3.  Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.

Authors:  N W Barton; F S Furbish; G J Murray; M Garfield; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205
  3 in total
  6 in total

1.  Enzyme replacement in neuronal storage disorders in the pediatric population.

Authors:  Erika F Augustine; Jonathan W Mink
Journal:  Curr Treat Options Neurol       Date:  2013-10       Impact factor: 3.598

2.  Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment.

Authors:  Filippo Vairo; Cristina Netto; Alicia Dorneles; Suzana Mittelstadt; Matheus Wilke; Divair Doneda; Kristiane Michelin; Camila Blos Ribeiro; Amanda Quevedo; Tatiane Vieira; Tatiele Nalin; Sônia Lueska; Ida Vanessa D Schwartz
Journal:  JIMD Rep       Date:  2013-02-21

3.  Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry.

Authors:  Anna Tylki-Szymańska; Ashok Vellodi; Amal El-Beshlawy; J Alexander Cole; Edwin Kolodny
Journal:  J Inherit Metab Dis       Date:  2010-01-19       Impact factor: 4.982

4.  Management of neuronopathic Gaucher disease: revised recommendations.

Authors:  A Vellodi; A Tylki-Szymanska; E H Davies; E Kolodny; B Bembi; T Collin-Histed; E Mengel; A Erikson; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-08-05       Impact factor: 4.982

5.  Assessment of Basal Metabolic Rate and Nutritional Status in Patients with Gaucher Disease Type III.

Authors:  Divair Doneda; Filippo P Vairo; André L Lopes; Alvaro Reischak-Oliveira; Pedro Schestatsky; Marino M Bianchin; Cileide C Moulin; Ida V D Schwartz
Journal:  JIMD Rep       Date:  2013-12-17

6.  Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey.

Authors:  Ida Vanessa D Schwartz; Özlem Göker-Alpan; Priya S Kishnani; Ari Zimran; Lydie Renault; Zoya Panahloo; Patrick Deegan
Journal:  Mol Genet Metab Rep       Date:  2017-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.